2023, Volume 26, Issue 7
Engineering >> 2023, Volume 26, Issue 7 doi: 10.1016/j.eng.2023.03.008
Serum N-Glycan Markers for Diagnosing Significant Liver Fibrosis and Cirrhosis in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels
a Department of Microbiology & Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
b Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing 100034, China
c Sysdiagno (Nanjing)Biotechnology Company Limited, Nanjing 211800, China
# These authors contributed equally to this work.
Next Previous
Abstract
The aim of this study was to explore the role of serum N-glycomic-derived models in diagnosing significant liver fibrosis and cirrhosis in 285 chronic hepatitis B (CHB) patients with normal (< 40 IU·L–1) alanine aminotransferase (ALT) levels. Liver biopsies were performed in all enrolled patients, and the stages of liver fibrosis were assessed using the Ishak scoring system. Serum N-glycan profiles were tested using DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE). A total of nine N-glycan peaks were identified in serum samples for each subject. A machine learning method—namely, random forest (RF) analysis—was adopted to construct more ideal serum N-glycan models in order to distinguish significant liver fibrosis (≥ F3) and cirrhosis (≥ F5). The diagnostic value of the constructed N-glycan models and other fibrotic markers was evaluated. The liver biopsy results revealed that 63.86% (182/285) and 16.49% (47/285) of patients had significant liver fibrosis and cirrhosis, respectively, and 4.91% (14/285) of patients had significant inflammation. In distinguishing significant liver fibrosis, the diagnostic efficiency of the serum N-glycan RF model constructed for distinguishing significant liver fibrosis (≥ F3; RF-A model) was excellent (area under receiver operating characteristic (AUROC) curve: 0.94), and the coincidence rate of the serum N-glycan RF-A model compared with liver biopsy was 90.45%. In distinguishing liver cirrhosis, the diagnostic AUROC curve of the serum N-glycan RF model constructed for distinguishing liver cirrhosis (≥ F5; RF-B model) was 0.97, and the coincidence rate was 88.94%. The diagnostic efficiency of the constructed serum N-glycan models (RF-A and RF-B) was superior to that of liver stiffness measurement (LSM), the fibrosis index based on the four factors (FIB-4), and the aspartate aminotransferase-to-platelet ratio index (APRI). Serum N-glycan models are promising markers for the differentiation of significant liver fibrosis and cirrhosis in CHB patients with normal ALT levels.
Keywords
Liver fibrosis ; Chronic hepatitis B ; Serum N-glycan ; N-glycan model ; Alanine aminotransferase (ALT) level
SupplementaryMaterials
Figures
Fig. 1
Fig. 2
Fig. 3
References
[ 1 ] World Health Organization. Progress report on HIV, viral hepatitis and sexually transmitted infections 2019. Accountability for the global health sector strategies, 2016–2021. Geneva: World Health Organization; 2021.
[ 2 ] Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen DS, Van Damme P, Abbas Z, et al.; the Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol 2018;3(6):383–403. link1
[ 3 ] Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells 2020;9(4):875. link1
[ 4 ] Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. Korean J Intern Med 2017;32(2):213–28. link1
[ 5 ] Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018;67(4):1560–99. link1
[ 6 ] Kao JH, Hu TH, Jia J, Kurosaki M, Lim YS, Lin HC, et al. East Asia expert opinion on treatment initiation for chronic hepatitis B. Aliment Pharmacol Ther 2020;52(10):1540–50. link1
[ 7 ] Chinese Society of Infectious Diseases, Chinese Society of Hepatology. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Chin J Hepatol 2019;27(12):938–61. Chinese.
[ 8 ] Agbim U, Asrani SK. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. Expert Rev Gastroenterol Hepatol 2019;13(4):361–74. link1
[ 9 ] Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol 2014;20(45):16820–30. link1
[10] Caballería L, Torán P, Caballería J. Markers of hepatic fibrosis. Med Clin 2018;150(8):310–6. link1
[11] Guha IN, Rosenberg WM. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities. Clin Liver Dis 2008;12 (4):883–900. link1
[12] Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: a metaanalysis. Gastroenterology 2008;134(4):960–74. link1
[13] Yu JH, Lee JI. Current role of transient elastography in the management of chronic hepatitis B patients. Ultrasonography 2017;36(2):86–94. link1
[14] Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep 2020;2(2):100067. link1
[15] An HJ, Kronewitter SR, de Leoz ML, Lebrilla CB. Glycomics and disease markers. Curr Opin Chem Biol 2009;13(5–6):601–7. link1
[16] Callewaert N, Geysens S, Molemans F, Contreras R. Ultrasensitive profiling and sequencing of N-linked oligosaccharides using standard DNA-sequencing equipment. Glycobiology 2001;11(4):275–81. link1
[17] Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004;10(4):429–34. link1
[18] Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, et al. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics 2009;8 (5):986–94. link1
[19] Cao X, Shang QH, Chi XL, Zhang W, Xiao HM, Sun MM, et al. Serum N-glycan markers for diagnosing liver fibrosis induced by hepatitis B virus. World J Gastroenterol 2020;26(10):1067–79. link1
[20] Liu XE, Desmyter L, Gao CF, Laroy W, Dewaele S, Vanhooren V, et al. Nglycomic changes in hepatocellular carcinoma patients with liver cirrhosis induced by hepatitis B virus. Hepatology 2007;46(5):1426–35. link1
[21] Cong M, Ou X, Huang J, Long J, Li T, Liu X, et al. A predictive model using Nglycan biosignatures for clinical diagnosis of early hepatocellular carcinoma related to hepatitis B virus. OMICS 2020;24(7):415–23. link1
[22] Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22(6):696–9. link1
[23] Raffetti E, Fattovich G, Donato F. Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and metaanalysis. Liver Int 2016;36(9):1239–51. link1
[24] Lai M, Hyatt BJ, Nasser I, Curry M, Afdhal NH. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007;47 (6):760–7. link1
[25] Chao DT, Lim JK, Ayoub WS, Nguyen LH, Nguyen MH. Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase 40 IU/L and significant hepatic fibrosis. Aliment Pharmacol Ther 2014;39(4):349–58. link1
[26] Kumar M, Sarin SK, Hissar S, Pande C, Sakhuja P, Sharma BC, et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008;134 (5):1376–84. link1
[27] Duan M, Chi X, Xiao H, Liu X, Zhuang H. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B. Hepatol Int 2021;15(2):318–27. link1
[28] Sonneveld MJ, Brouwer WP, Hansen BE, Chan HL, Piratvisuth T, Jia JD, et al.; the SONIC-B Study Group. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. Aliment Pharmacol Ther 2020;52(8):1399–406. link1
[29] Wang W. Glycomedicine: the current state of the art. Engineering. In press.
[30] Taniguchi N, Takahashi M, Kizuka Y, Kitazume S, Shuvaev VV, Ookawara T, et al. Glycation vs. glycosylation: a tale of two different chemistries and biology in Alzheimer’s disease. Glycoconj J 2016;33(4):487–97. link1
[31] Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell 2006;126(5):855–67. link1
[32] Qu Y, Gao CF, Zhou K, Zhao YP, Xu MY, Lu LG. Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B. Ann Hepatol 2012;11(2):202–12. link1
[33] Gornik O, Wagner J, Pucic´ M, Knezevic´ A, Redzic I, Lauc G. Stability of N-glycan profiles in human plasma. Glycobiology 2009;19(12):1547–53. link1
[34] Bao L, Sun Z. Identifying genes related to drug anticancer mechanisms using support vector machine. FEBS Lett 2002;521(1–3):109–14. link1
[35] Li W, Huang Y, Zhuang BW, Liu GJ, Hu HT, Li X, et al. Multiparametric ultrasomics of significant liver fibrosis: a machine learning-based analysis. Eur Radiol 2019;29(3):1496–506. link1
[36] Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol 2015;21 (41):11567–83. link1
[37] Castera L, Pinzani M. Biopsy and non-invasive methods for the diagnosis of liver fibrosis: does it take two to tango? Gut 2010;59(7):861–6. link1
[38] Castera L. Hepatitis B: are non-invasive markers of liver fibrosis reliable? Liver Int 2014;34(Suppl 1):91–6. link1
[39] Kim SU, Kim DY, Park JY, Lee JH, Ahn SH, Kim JK, et al. How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B? J Clin Gastroenterol 2010;44(1):66–71. link1
[40] Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasoundbased transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007;5(10):1214–20. link1
[41] Tan YW, Zhou XB, Ye Y, He C, Ge GH. Diagnostic value of FIB-4, aspartate aminotransferase-to-platelet ratio index and liver stiffness measurement in hepatitis B virus-infected patients with persistently normal alanine aminotransferase. World J Gastroenterol 2017;23(31):5746–54. link1
[42] Xu Y, Zhang YG, Wang X, Qi WQ, Qin SY, Liu ZH, et al. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis. World J Gastroenterol 2015;21 (25):7869–76. link1
京公网安备 11010502051620号
